GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » Revenue

Divi's Laboratories (NSE:DIVISLAB) Revenue : ₹73,909 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories Revenue?

Divi's Laboratories's revenue for the three months ended in Dec. 2023 was ₹18,550 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹73,909 Mil. Divi's Laboratories's Revenue per Share for the three months ended in Dec. 2023 was ₹68.99. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹279.01.

Warning Sign:

Divi's Laboratories Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Divi's Laboratories was -9.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 13.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 17.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Divi's Laboratories's highest 3-Year average Revenue per Share Growth Rate was 45.70% per year. The lowest was -49.90% per year. And the median was 17.00% per year.


Divi's Laboratories Revenue Historical Data

The historical data trend for Divi's Laboratories's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories Revenue Chart

Divi's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48,038.20 52,911.70 68,583.40 87,992.30 76,659.40

Divi's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17,080.00 18,489.40 17,780.00 19,090.00 18,550.00

Competitive Comparison of Divi's Laboratories's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Revenue distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Revenue falls into.



Divi's Laboratories Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹73,909 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Divi's Laboratories  (NSE:DIVISLAB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Divi's Laboratories Revenue Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories (NSE:DIVISLAB) Business Description

Traded in Other Exchanges
Address
Divi Towers, 1-72/23(P)/DIVIS/303, Babukhan Lane, Cyber Hills, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. The company has three distinct business segments: Generic APIs, Custom Synthesis, and Nutraceuticals. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Divi's Laboratories (NSE:DIVISLAB) Headlines

No Headlines